| Literature DB >> 27446499 |
Anna Subiel1, Reece Ashmore1, Giuseppe Schettino1.
Abstract
Research on the application of high-Z nanoparticles (NPs) in cancer treatment and diagnosis has recently been the subject of growing interest, with much promise being shown with regards to a potential transition into clinical practice. In spite of numerous publications related to the development and application of nanoparticles for use with ionizing radiation, the literature is lacking coherent and systematic experimental approaches to fully evaluate the radiobiological effectiveness of NPs, validate mechanistic models and allow direct comparison of the studies undertaken by various research groups. The lack of standards and established methodology is commonly recognised as a major obstacle for the transition of innovative research ideas into clinical practice. This review provides a comprehensive overview of radiobiological techniques and quantification methods used in in vitro studies on high-Z nanoparticles and aims to provide recommendations for future standardization for NP-mediated radiation research.Entities:
Keywords: DNA damage; Monte Carlo.; clonogenic assay; gold nanoparticle; reactive oxygen species
Mesh:
Year: 2016 PMID: 27446499 PMCID: PMC4955064 DOI: 10.7150/thno.15019
Source DB: PubMed Journal: Theranostics ISSN: 1838-7640 Impact factor: 11.556
Figure 1Graphical representation of quantification of NP-mediated radiation enhancement effect from clonogenic survival data using: (a) SERNP=MIDCont/MIDNP; (b) DMRx%= DCont/DNP at x% effect is calculated as follows: (1) % survival is selected, (2) dose DCont is evaluated, (3) dose DNP is evaluated for the same % survival; (c) DEFx = Dx,Gy (no NPs) / Dx,Gy (with NPs) is calculated through estimation of the SF level through the following steps: (1) Dx Gy (no NP) is chosen, (2) SF at Dx,Gy (no NP) is evaluated, (3) Dx,Gy (with NPs) is calculated); (d) REF = D0,NP / D0,Cont; (e) RERxGy = SFxGy,Cont / SFxGy,NP.
Overview of modification enhancement ratios used in nanoparticle studies.
| Cell line | Radiation source | NP material (size) | Enhancement factor used | Reference |
|---|---|---|---|---|
| GES-1 | 4 MeV electrons | DOC-NP | REF = D0,NP / D0,Cont | [58] |
| MDA-MB-231 | 225 kVp X-rays | Au-NP | DEF2Gy | [56] |
| DU-145 | 160 kVp X-rays | Au-NP | DEF2Gy | [62] |
| HeLa | Co-60 | Au-NP | RER2Gy | [59] |
| HeLa | 105 kVp X-rays | Au-NP | DMR10% | [17] |
| RT112 | 250 kVp X-rays | Au-NP | DMR50% | [47] |
| MDA-MB-23 | 160 kVp X-rays | Au-NP | α, β - qualitative analysis | [44] |
| MDA-MB-23 | 225 kVp X-rays | Au-NP | DMR10% | [41] |
| MDA-MB-23 | 160 kVp X-rays | Au-NP | SER | [36] |
| DU145 | 160 kVp X-rays | Au-NP | SER | [16] |
| MDA-MB-23 | 6 MV X-rays | Au-NP | SER | [37] |
| DU145 | 160 kVp X-rays | Au-NP | RER3Gy | [54] |
| BAECs | 80 kVp X-rays | Au-NP | DMR90% | [49] |
| CT26 | synchrotoron X-ray | Au-NP | SF3 | [55] |
| F98 | 50 keV synchrotoron X-ray | Au-NP | DMR10% | [45] |
| MDA-MB-361 | 100 kVp X-rays | Au-NP | DMR10% | [46] |
| HeLa | Co-60 | Glu-Au-NP | DMR90% | [50] |
| SNB-19 | MeV photons (LINAC) | Ti-NP | SF2 | [43] |
| BAOEC | 30-100 keV synchrotron X-rays | Au-NP | DMR90% | [42] |
| HeLa | Cs-137 | PEG-Au-NP (4.8 - 47 nm) | DMR50% | [48] |
| A549 | 6 MV X-rays | Glu-Au-NP (13 nm) | SER | [38] |
| HT1080 | Co-60 | NBTXR3-NP (50 nm) | DEF4Gy DEF8Gy | [57] |
| GBM | 150 kVp X-rays | Au-NP | RER4Gy | [60] |
| U87 | Cs-137 | Gd2O3-NP (sub-10 nm) | SF2 | [63] |
| Panc1 | 220 kVp | AGuIX-NP | SER | [61] |
| U87 | Cs-137 | BSA-Au-NP | DEF2Gy | [64] |
| MDA-MB-231 | 6 MV | Glu-Au-NP | SER | [40] |
| PC3 | 6 MV | PEG-Au-NP | DMR20% | [65] |
Methods used in the literature for assessment of NP uptake, intracellular distribution and cell cycle.
| Ref. | NP uptake assessment | Quantification of uptake | Intracellular distribution/localization | Cell cycle assessment |
|---|---|---|---|---|
| [73] | ICP-AES | pg/cell | TEM | Flow cytometry |
| [65] | ICP-MS | Relative concentration of internalized gold | TEM | n/a |
| [41] | ICP-AES | pg/cell | TEM | n/a |
| [36] | ICP-AES | # of NP/cell | TEM | n/a |
| [63] | ICP-OES | pg/cell | TEM | n/a |
| [37] | ICP-AES | # of NP/cell | TEM | Flow cytometry |
| [82] | n/a | n/a | TEM | n/a |
| [79] | ICP analysis | # of NP/cell | TEM | n/a |
| [71] | ICP-MS | # of NP/cell | n/a | Flow cytometry |
| [83] | n/a | n/a | TEM | n/a |
| [80] | ICP-MS | # of NP/cell | TEM | n/a |
| [84] | n/a | n/a | TEM | n/a |
| [48] | n/a | n/a | TEM | n/a |
| [50] | n/a | n/a | TEM | n/a |
| [59] | ICP-AES | # of NP/cell | n/a | n/a |
| [81] | ICP-AES | # of NP/cell | n/a | Flow cytometry |
Overview of ROS fluorescence measurement in NP studies.
| Probe | Intensity measurement method | NP effect quantification method | Reference |
|---|---|---|---|
| APF | Microplate reader | INP+Ir / IIrr | [114] |
| Flow cytometry | INP+Irr / IControl | [62] | |
| Fluorimeter | INP+Irr / IControl | [94] | |
| Spectrofluorometer | INP+Irr / IControl | [102] | |
| Confocal microscope | INP+Irr / IControl | [81] | |
| Not stated | Qualitative comparison of INP+Irr and INP | [88] | |
| Flow cytometry | INP+Irr / IIrr | [54] | |
| Flow cytometry | INP+Irr / IControl | [58] | |
| Spectrofluorometer | INP+Irr / IControl | [103] | |
| Microplate reader | INP+Irr / IControl | [115] |
Nanoparticle studies employing γ-H2AX and 53BP1 assays. In the “quantification of enhancement column” FC stands for “N of foci” and the subscript indicates: “NP+Irr” = irradiated samples treated with NPs, “NP” = un-irradiated samples treated with NPs, “Irr” = irradiated samples without NPs and “Cont” = un-irradiated samples without NP.
| Dose | Quantification of enhancement | Method of scoring | Time of fixing after radiation | Dynamics evaluated | Ref. |
|---|---|---|---|---|---|
| 0 - 1.1 Gy | FCNP+Irr / FCCont | Information not provided | 24 h | No | [144] |
| 5 Gy | FCNP+Irr / FCCont | 1 h | No | [63] | |
| 2 Gy | Qualitative | Information not provided | 1 h | No | [143] |
| 1 Gy | Qualitative | Information not provided | 30 min | No | [62] |
| 0.5 Gy | FCNP+Irr / FCCont | Customised | 30 min | No | [46] |
| 2 Gy | Qualitative | Information not provided | 1 h, 24 h | No | [43] |
| 2 Gy | FCNP+Irr / FCCont | Manually under microscope view | 1 h, 24 h | No | [56] |
| 1 Gy | Qualitative | Information not provided | 1 h, 24 h | No | [16] |
Monte Carlo studies on radiation therapy enhancement by high-Z nanoparticles. In the “Dose enhancement” column stands for MC-calculated absorbed dose by the tumour treated with NPs while represents the absorbed dose in the tumour without NPs.
| MC code (electron cutoff energy) | Radiation | Simulation type | Medium | Dose enhancement | Reference |
|---|---|---|---|---|---|
| Geant4-DNA | 80 kVp | Step-by-step, all interactions simulated explicitly | Water, Au | [86] | |
| MCNP5 | 300 kVp | MCNP5: condensed histories method | ICRU four-component soft tissue, | [74] | |
| EGSnrc | 125I | EGSnrc: condensed history method | Water | [152] | |
| PENELOPE | 200 kVp | Step-by-step simulations | Water with (Hafnium oxide -NP) | [57] | |
| Geant4-DNA | 20-150 kVp | Step-by-step simulations | Water, Au | Relative Biological Effectiveness (RBE) calculated through Local Effect Model (LEM) | [44] |
| MCNPX v.2.6.0 (1 keV) | 50-120 keV | Condensed histories method | Water, Au | [156] | |
| Geant4 | 68 kVp | Condensed histories method | Water, Au | [159] | |
| Geant4 | 192Ir | Condensed histories method | Water, Au | [160] | |
| Geant4 | Condensed histories method | Water, Au | [154] | ||
| MCNP5 | 125Ir | Condensed histories method | ICRU four-component soft tissue, Au | [155] | |
| Geant4 | 50, 250 keV, | Condensed histories method | Water, Au | [161] | |
| EGSnrc | 40 kVp | Condensed histories method | Water, Au | [153] | |
| EGSnrc | 140 kVp | Condensed histories method | ICRU four-component soft tissue, Au | [147] | |
| Not stated | 100 kVp | Not stated | Water, Au | Enhancement factor reported, but no details provided | [162] |
Figure 2Correlation between different quantification factors: (A) DMR at 50% survival, (B) DMR at 10% survival, (C), DMR at 1% survival, (D) α/β ratio, (E) DEF at 2 Gy, (F) RER at 2 Gy as a function SER.